Status:
COMPLETED
Influence of Aliskiren on Proteinuria
Lead Sponsor:
Medical University of Gdansk
Conditions:
Chronic Kidney Disease
Proteinuria
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
To evaluate the proteinuria lowering efficacy as well as tolerability and safety of the renin inhibitor aliskiren compared with that of placebo and angiotensin converting enzyme inhibitor perindopril ...
Detailed Description
Proteinuria is a major risk factor for progression to end-stage renal disease in both diabetic and nondiabetic nephropathies. Angiotensin II and aldosterone are the key players in the development of r...
Eligibility Criteria
Inclusion
- age 18-65 years
- chronic non-diabetic proteinuric nephropathy
- creatinine clearance above 30 ml/min
- stable proteinuria above 500 mg/ 24 hours
- blood pressure above 125/75 mmHg and below 150/95 mmHg
- no steroids or other immunosuppressive treatment for a minimum of six months before the study
Exclusion
- unstable coronary heart disease
- decompensated congestive heart failure in the previous 6 months
- episode of malignant hypertension or stroke in the history
- diabetes
- creatinine clearance below 30 ml/min
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01219413
Start Date
March 1 2009
End Date
September 1 2010
Last Update
September 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Gdansk
Gdansk, Pomeranian Voivodeship, Poland, 80-211